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loom’s syndrome is a rare autosomal recessive genetic
disorder characterized by chromosomal aberrations,
genetic instability, and cancer predisposition, all of
which may be the result of abnormal signal transduction
during DNA damage recognition. Here, we show that BLM
is an intermediate responder to stalled DNA replication
forks. BLM colocalized and physically interacted with
the DNA damage response proteins 53BP1 and H2AX. Al-
though BLM facilitated physical interaction between p53 and
53BP1, 53BP1 was required for efﬁcient accumulation of
B
 
both BLM and p53 at the sites of stalled replication. The
accumulation of BLM/53BP1 foci and the physical inter-
action between them was independent of 
 
 
 
-H2AX. The
active Chk1 kinase was essential for both the accurate focal
colocalization of 53BP1 with BLM and the consequent
stabilization of BLM. Once the ATR/Chk1- and 53BP1-
mediated signal from replicational stress is received, BLM
functions in multiple downstream repair processes, thereby
fulﬁlling its role as a caretaker tumor suppressor.
 
Introduction
 
53BP1, first identified as a p53-interacting protein in a two-
hybrid screen (Iwabuchi et al., 1994), is a BRCT motif–
containing protein that responds rapidly to different types of
DNA damage (Schultz et al., 2000). It is a key transducer
protein that is involved in p53 accumulation, as well as G2-M
and intra–S-phase checkpoint arrest in response to ionizing
radiation (IR; Fernandez-Capetillo et al., 2002; Wang et al.,
2002). 53BP1 accumulation at sites of IR-induced double-
strand breaks (DSBs) requires 
 
 
 
-H2AX and a physical associa-
tion between the two proteins (Celeste et al., 2002; Fernandez-
Capetillo et al., 2002; Ward et al., 2003a). This response
involves the ATM-dependent checkpoint pathway, thought
to be constitutively active in certain human cancers (Rappold
et al., 2001; DiTullio et al., 2002). 53BP1 and other DNA
damage sensor proteins, like NFBD1/MDC1-NBS1, function
in parallel interacting pathways and also activate ATM in
response to IR (Mochan et al., 2003). The roles of 53BP1 in
the DNA damage response and in maintaining genomic
stability  were confirmed recently in knockout (KO) mice
(Ward et al., 2003b).
Though the involvement of H2AX and 53BP1 in response
to IR has been extensively investigated, much less is known
about the role of sensor proteins during replicational
stress. Replicational stress can arise when DNA replication is
blocked by DNA damage, induced by agents such as UV
radiation or hydroxyurea (HU). The 
 
Saccharomyces cerevisiae
 
PI3K-related kinase Mec1 and its most closely related mam-
malian homologue, ATR, are thought to control the cellular
responses to replicational stress. ATR carries out its function
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mainly by activating Chk1 through phosphorylation of serines
317 and 345 (Abraham, 2001; Bartek and Lukas, 2003).
BLM, a member of the RecQ family of DNA helicases,
has been characterized as a “genome caretaker” (Hickson,
2003). BLM is mutated in Bloom’s syndrome (BS) patients,
whose cells have abnormal DNA replication and elevated
rates of homologous recombination (HR). This is mani-
fested by an accumulation of abnormal replication interme-
diates and high rates of sister chromatid exchanges (SCEs;
van Brabant et al., 2000; Hickson, 2003). BLM can catalyze
branch migration of Holliday junctions in vitro, which may
prevent the collapse of replication forks and resultant DSBs
(Karow et al., 2000). BLM helicase and topoisomerase III
 
 
 
cooperate to resolve recombination intermediates during
HR (Wu and Hickson, 2003). Thus, BLM has been pro-
posed to function at the interface of replication and recom-
bination and to facilitate the repair of DNA damage.
BLM interacts physically and functionally with a variety
of proteins involved in tumor suppression, DNA recombi-
nation, and replication. BLM is a responder to DNA dam-
age; rapidly colocalizes to DSBs, as visualized by its colocal-
ization with 
 
 
 
-H2AX (Davalos and Campisi, 2003); binds
to p53 (Wang et al., 2001); and transports it to stalled DNA
replication forks, resulting in modulation of HR by comple-
mentary pathways (Sengupta et al., 2003). Exposure of cells
to either IR or replicational stress causes BLM to colocalize
and physically interact with RAD51 and RAD54 at stalled
DNA replication forks (Wu et al., 2001; Sengupta et al.,
2003). The helicase is also part of a putative multiprotein
complex (BASC) present at stalled replication foci and colo-
calizes with BRCA1, MLH1, MRE11-RAD50-NBS1 com-
plex, RPA, ATR, and ATM (Wang et al., 2000). BLM is
phosphorylated by ATM kinase following IR, though the
ATM-targeted phosphorylation sites are not critical for BLM
function in SCE suppression (Beamish et al., 2002). Recently,
it has been reported that the NH
 
2
 
-terminal phosphorylation
of Thr-99 and Thr-122 on BLM by ATR is required to re-
cover from S-phase arrest (Davies et al., 2004).
Because BLM, 53BP1, and p53 have the potential to be
functionally involved during replicational stress, we sought
to investigate their interaction in the context of other major
proteins involved in the signal transduction process. Using
hTERT immortalized (nontransformed) normal human fi-
broblasts (NHFs), we demonstrated that endogenous BLM
and 53BP1 colocalized rapidly at stalled DNA replication
forks and physically interacted with each other. Using iso-
genic cell lines, gene KO models, and siRNA or antisense
(AS)-treated cells, we have shown that BLM facilitated the
interaction between p53 and 53BP1 during replicational
stress. 53BP1 regulated the accumulation of BLM at sites of
DNA damage even in the absence of 
 
 
 
-H2AX. The up-
stream signal to BLM was predominantly carried through
the ATR–Chk1 kinase pathway. Active Chk1 kinase was es-
sential for the accurate focal colocalization of both 53BP1
and BLM at stalled DNA replication forks and the stabiliza-
tion of the helicase. These results demonstrate that BLM is a
responder to DNA damage during replicational stress and
imply that functional interactions among BLM, 53BP1, and
p53 are required for transmitting the DNA damage signal to
downstream repair mechanisms.
 
Results
 
BLM is an intermediate responder to replicational stress
 
In asynchronous NHFs, few nuclear foci of BLM (4–15 per
cell) or p53 (2–8 per cell) were present, nor was there signif-
icant colocalization of BLM and p53 (unpublished data).
These data were similar to findings we have reported previ-
ously (Sengupta et al., 2003). As reported elsewhere (Schultz
et al., 2000; Rogakou et al., 1999; Anderson et al., 2001),
neither 
 
 
 
-H2AX nor 53BP1 foci were visible in nonstressed
asynchronous NHFs (unpublished data).
To study replicational stress, cells were synchronized in G0
by growth to confluence, released by replating at low density
for 24 h, and then treated with HU for 6 h. Using this pro-
tocol, we observed 
 
 
 
60–70% of the cells were present in
S-phase (after 6 h of HU treatment), established either by
flow cytometry (not depicted) or by BrdU incorporation
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200405128/DC1). We and others have demonstrated
that, during HU treatment, BLM accumulates at stalled
DNA replication forks, as visualized by pulse-labeled BrdU
incorporation (Sengupta et al., 2003) or PCNA staining
(Davies et al., 2004). To determine whether 
 
 
 
-H2AX was
also involved in the response to HU-induced stalled DNA
replication forks, we performed a time course for the ac-
cumulation of endogenous 
 
 
 
-H2AX protein and foci, as
well as the colocalization of 
 
 
 
-H2AX foci with pulse-labeled
BrdU (after DNase treatment). The nuclei were visualized af-
ter preextraction, which removed the soluble nucleoplasm.
Hence, only the proteins that were bound to the insoluble
matrix were visualized. During HU treatment, 
 
 
 
-H2AX
protein increased with time (Fig. 1 C, a). Correspondingly,
 
 
 
-H2AX foci accumulated and colocalized appreciably with
BrdU within 30 min as previously reported (Fig. 1 A; Dava-
los and Campisi, 2003). Although endogenous 53BP1 pro-
tein levels remained unchanged during HU treatment (Fig. 1
C, b), 53BP1 foci appeared with similar kinetics as 
 
 
 
-H2AX
foci (Fig. 1 A). BLM and p53 protein levels increased with
similar kinetics (Fig. 1 C, c and d). BLM foci were detected
within 30 min and increased in number and degree of colo-
calization (as measured by colocalization factor, defined in
Materials and methods) with BrdU (Sengupta et al., 2003;
unpublished data). Moreover, a time-dependent enhance-
ment of BLM and 53BP1 foci colocalization was also ob-
served (Fig. 1, A and B). BLM foci appeared earlier than p53
foci, and the number of p53 foci was always less than the
number of 
 
 
 
-H2AX, 53BP1, or BLM foci. Within 6 h, al-
most all BLM and p53 foci colocalized with 53BP1 foci (Fig.
1, A and B). The colocalization factors for the same pairs of
foci were much less when the cells were subjected to the same
synchronization protocol, but were not treated with HU, in-
dicating that the colocalization were a result of HU-mediated
replicational stress and not due to the synchronization proto-
col (Fig. S1 B). These results indicate that 
 
 
 
-H2AX, 53BP1,
BLM, and p53 likely function in the same response pathway.
We next investigated the rate of focal accumulation
and colocalization of proteins involved in different DNA re-
pair pathways like HR, in which proteins like MRE11 and
RAD51 are involved. The colocalization of MRE11 and
RAD51 foci with sites of stalled DNA replication forks (as
measured by their colocalization with 53BP1 foci) never ex- 
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ceeded 45% even after 6 h of HU treatment (Fig. S1, C and
D). Thus, although MRE11 and RAD51 apparently func-
tion in the same replicational stress pathway as 
 
 
 
-H2AX,
53BP1, BLM, and p53, they also appear to possess distinct
divergent localization and functions.
 
BLM and 53BP1 have an inter-regulatory relationship
 
We have previously demonstrated that BLM, p53, and
RAD51 colocalize and physically interact as part of a multi-
protein complex at the sites of stalled DNA replicational
forks. Moreover, BLM is involved in the recruitment of p53
to these sites (Sengupta et al., 2003). As an extension of our
previous work, we found that 53BP1 and p53 were also
present in BLM immunoprecipitates of HU-treated NHFs
(Fig. 2 A). Reciprocally, 53BP1 was also present in p53
immunoprecipitates (Fig. 2 B). Due to possible steric inter-
ference, BLM could not be detected in p53 immunopre-
cipitates (Wang et al., 2001; unpublished data). BLM
immunoprecipitates from p53-deficient NHF E6 cells con-
tained 53BP1 (Fig. 2 C). Consistent with this finding, BLM
Figure 1.  -H2AX, 53BP1, BLM, and 
p53 colocalize and accumulate with 
similar kinetics. (A) Time course of the 
accumulation of BrdU,  -H2AX, 53BP1, 
BLM, and p53 foci after HU treatment. 
NHFs were contact inhibited, split at 
low dilution, and treated with HU for 
the indicated time intervals. BrdU staining 
was done on washed cells and incubated 
with the nucleotide analogue for 10 min. 
Immunofluorescence was performed 
with antibodies against BrdU/ -H2AX 
(a); 53BP1 (monoclonal)/ -H2AX (b); 
53BP1 (monoclonal)/BLM (ab476) (c); 
and 53BP1 (monoclonal)/p53 (CM1) (d). 
Bars, 5  m. (B) Quantitation of A. The 
graphs represent mean   SD. (C) The 
accumulation of proteins after HU treat-
ment. Western blots were performed 
with anti- -H2AX (a), anti-53BP1 (poly-
clonal; b), anti-BLM (C-18) (c), anti-p53 
(DO-1) (d), and anti-TBP antibodies (e). 
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and 53BP1 accumulates at stalled replication forks in HU-
arrested cells, and 53BP1 colocalized with both 
 
 
 
-H2AX
and BLM foci in p53-deficient cells (Fig. 2 E), indicating
that p53 is dispensable for focal accumulation and physical
interaction of BLM and 53BP1. Though p53 immunopre-
cipitates from BLM-deficient BS cells contained low levels
of 53BP1, the p53–53BP1 interaction was not enhanced by
replicational stress (Fig. 2 D). Thus, BLM facilitated the
physical interaction between 53BP1 and p53 in vivo. Inter-
estingly, 53BP1 accumulated at 
 
 
 
-H2AX foci in synchro-
nized HU-arrested cells even in the absence of BLM protein
(Fig. 2 F, b), suggesting that BLM was dispensable for
53BP1 focal accumulation.
To investigate if 53BP1 affected the localization of BLM
or p53, experiments were performed using murine or hu-
man cells, where 53BP1 was either absent or decreased (Fig.
Figure 2. 53BP1 interacts with p53 via BLM. (A and C) The immunoprecipitation of BLM revealed 53BP1 in NHFs and NHF E6. NHFs (A) 
and NHF E6 (C) were either left asynchronous (lane 1) or contact inhibited, split at low dilution, and treated with HU (lane 2) for 6 h. 400  g of 
lysates were immunoprecipitated with antibodies against BLM (C-18) in the absence (lanes 3 and 4) or presence (lane 5) of the blocking peptide. 
Input (lanes 1 and 2) indicates 10% of the lysate was used for immunoprecipitation. The efficiency of immunoprecipitation was verified with 
self-antibody (a). The BLM immunoprecipitates were probed with anti-53BP1 (polyclonal; for both A and C, b) and anti-p53 (DO-1) (for A only, 
c) antibodies. Lanes 1 and 3, minus HU; lanes 2, 4, and 5, plus HU. (B and D) Immunoprecipitation of p53 revealed 53BP1 in NHFs, but not in 
BS. Same as in A and C, except NHFs were used in B and BS in D. Immunoprecipitation was done with antibodies against p53 (DO-1) (lanes 3 
and 4) or against the corresponding IgG (lane 5). The p53 immunoprecipitates were probed with polyclonal anti-53BP1 antibody (b). (E)  -H2AX, 
53BP1, and BLM colocalize in the absence of p53. NHFs or NHF E6 were prepared as in A and treated with HU for 6 h. Immunofluorescence was 
performed with antibodies against  -H2AX/53BP1 (monoclonal; a) and BLM (ab476)/53BP1 (monoclonal; b). Bars, 5  m. (F) 53BP1 accumulates 
at the sites of stalled replication forks even in the absence of BLM. Same as in E except, BS and BS A-15 cells were used. Bars, 5  m. 
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3). The primary murine embryo fibroblasts (MEFs) used at
passage 2–3 retained their wild-type (WT) p53 gene se-
quence and functions (induction of p21 due to DNA dam-
age; unpublished data). In WT MEFs, 53BP1 colocalized
with both BLM and p53 in discrete foci outside nucleoli
during HU treatment. However, in HU-treated 53BP1 KO
MEFs, BLM staining was detected in nucleoli, whereas p53
foci were almost completely absent. Nucleolar sequestration
of BLM in KO MEFs was confirmed by colocalization of
BLM with nucleolin (Fig. 3 A).
The results with murine cells were cross-validated in
NHFs, in which 53BP1 was decreased by using a previously
published siRNA (DiTullio et al., 2002). The same synchro-
nization and HU treatment protocol was used, except that
two sequential 53BP1 siRNA transfections were conducted
just before growth to confluence. Both the control and
53BP1 siRNA-transfected cell populations contained 
 
 
 
60%
S-phase cells after 6 h of HU treatment, as analyzed by flow
cytometry and BrdU incorporation (Fig. S2, A and B, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200405128/
DC1; and not depicted). 53BP1 depletion was not com-
plete, which led to the appearance of residual protein and
53BP1 foci in 
 
 
 
30% of the HU-treated cells (Fig. 3, B and
C). In control siRNA-transfected cells (and also a subpopu-
lation of 53BP1 siRNA-treated cells), 53BP1 colocalized ex-
tensively with BLM and p53 (Fig. 3, C and D), whereas
BrdU staining colocalized with BLM and 53BP1 (Fig. S2 C,
a and b). Although 53BP1 siRNA-treated cells exhibited
stalled replication forks as visualized by BrdU staining, the
focal accumulation of both BLM and p53 foci was greatly
diminished when compared with control cells after HU
treatment (Fig. 3, C and D; and Fig. S2 C, c). BLM accumula-
Figure 3. 53BP1 regulates the accumulation of BLM. (A) Absence of 53BP1 leads to nucleolar accumulation of BLM in KO MEFs. WT or 
53BP1 KO MEFs were treated with HU for 6 h. Immunofluorescence was performed with antibodies against BLM (ab476)/53BP1 (monoclonal; a); 
p53 (CM1)/53BP1 (monoclonal; b); and BLM (ab476)/nucleolin (c). (B) The interaction of BLM with 53BP1 and p53 is decreased in 53BP1siRNA-
treated cells. Control (lanes 1 and 2) or 53BP1 siRNA-transfected (lanes 3 and 4) NHFs were contact inhibited, split at low dilution, and grown 
either in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of HU for 6 h. 400  g of lysates were immunoprecipitated with antibodies 
against BLM (C-18) (lanes 5–9) in the absence (lanes 5–8) or presence (lane 9) of the blocking peptide. Input (lanes 1–4) indicates 10% of the 
lysate was used for immunoprecipitation. The efficiency of immunoprecipitation was verified with BLM (ab476) antibody (a). Antibodies used 
for the detection of other proteins in BLM immunoprecipitation were anti-53BP1 (polyclonal; b and d) and anti-p53 (DO-1) (c and e). Lanes 
1, 3, 5, and 7, minus HU; lanes 2, 4, 6, 8, and 9, plus HU. Panels d and e are longer exposures of the same blots in b and c. (C) The lack of 
53BP1 prevents the accumulation of BLM and p53. Transfection and treatment were done as in B. Immunofluorescence was performed with 
antibodies against BLM (ab476)/53BP1 (monoclonal)/DNA (DAPI) (a) and p53 (CM1)/53BP1 (monoclonal)/DNA (DAPI) (b). Fields were 
chosen that contained a cell in which 53BP1 expression was not suppressed as an internal control for cells lacking expression of 53BP1. 
Arrows indicate the position of cells lacking 53BP1 expression. (D) Quantitation of C. The histogram represents mean   SD. 
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tion in the nucleoli of 53BP1-depleted NHFs was much
less than in the 53BP1 KO MEFs, which probably reflects a
species difference, as has been reported for WRN, another
member of the RecQ family of helicases (Suzuki et al. 2001).
Thus, lack of 53BP1 prevents the accumulation of BLM and
p53 at stalled DNA replication forks in both human and
murine cells.
To confirm the interaction of 53BP1 and BLM, immuno-
precipitations were performed with BLM antibody in cell ly-
sates from control and 53BP1siRNA-treated NHFs. Equiva-
lent levels of BLM were immunoprecipitated in HU-treated
control and 53BP1 siRNA-treated cells. Although BLM
formed a complex with 53BP1 and p53 in control cells dur-
ing replicational stress, the amount of p53 and its complex
with BLM was diminished in cells in which 53BP1 levels
were decreased (Fig. 3 B, compare lanes 6 and 8). These re-
sults indicate that 53BP1 is upstream of BLM and regulates
its focal accumulation.
 
 
 
-H2AX is dispensable for the focal accumulation of 
BLM and 53BP1 during replicational stress
 
Exposure of MEFs to neocarzinostatin (NCS), which also
causes DSBs like IR (Povirk et al., 1988), did not change the
protein level of 53BP1 (unpublished data). Similar to IR,
53BP1 focal accumulation was diminished in NCS-treated
H2AX KO MEFs when compared with WT MEFs (Fig. S2
D). 53BP1 protein levels were similar in WT and KO
H2AX MEFs after HU treatment. BLM was induced to
similar levels in both genotypes in the presence of HU (Fig.
4 A). However, HU-dependent accumulation of both BLM
and 53BP1 foci occurred in both H2AX WT and KO MEFs
(Fig. 4 B). The colocalization factor for BLM/53BP1 was
close to 75% in KO MEFs (Fig. 4 C). Hence, unlike IR,
H2AX was dispensable for the accumulation of 53BP1 and
BLM to the replicational forks. Equivalent BLM immuno-
precipitates obtained from HU-treated WT and KO H2AX
MEFs also contained 53BP1 (Fig. 4 D, compare lanes 6 and
Figure 4. 53BP1 and BLM can accumulate and physically interact independently of  -H2AX. (A) The accumulation of proteins in WT and 
H2AX KO MEFs after HU. H2AX WT (lanes 1 and 2) and KO (lanes 3 and 4) cells were contact inhibited, split at low dilution, and grown 
either in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of HU for 6 h. Western blots were performed with anti-53BP1 (polyclonal; a), 
anti-BLM (ab476) (b), anti- -H2AX (c), and anti-TBP antibodies (d). (B) 53BP1 and BLM accumulate at the sites of stalled replication forks 
even in the absence of  -H2AX. MEFs were treated as in A. Immunofluorescence was performed with antibodies against  -H2AX /53BP1 
(monoclonal; a) and BLM (ab476)/53BP1 (monoclonal; b). Bars, 5  m. (C) Quantitation of B. The histogram represent mean   SD. (D) BLM 
interacts with 53BP1 and BLM even in the absence of H2AX. WT (lanes 1 and 2) or H2AX KO (lanes 3 and 4) MEFs were prepared as in A and 
were either left untreated (lanes 1 and 3) or treated with HU (lane 2 and 4) for 6 h. 400  g of lysates were immunoprecipitated with antibodies 
against BLM (ab476) (lanes 5–8) or corresponding IgG (lane 9). Input (lanes 1–4) indicates 10% of the lysate used for immunoprecipitation. 
The efficiency of immunoprecipitation was verified with BLM (ab476) antibody (a). Antibodies used for the detection of other proteins in BLM 
immunoprecipitation were anti-53BP1 (polyclonal) (b) and  -H2AX (c). Lanes 1, 3, 5, 7, minus HU; lanes 2, 4, 6, 8, and 9, plus HU. 
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8). These results indicate that BLM and 53BP1 form foci
and physically associate during replicational stress even in
the absence of 
 
 
 
-H2AX.
 
Chk1 regulates the accumulation of 53BP1 and 
BLM foci
 
Chk1 is involved in IR-induced S and G2/M checkpoints in
mammalian cells. Activated pChk1 kinase phosphorylates
targets like Cdc25C and p53 (Bartek and Lukas, 2003). To
determine whether replicational stress signaling to 53BP1/
BLM was transmitted through the ATR and Chk1 kinase
pathway, we used two independent approaches: a Chk1
siRNA (Zhao et al., 2002) or a Chk1 AS construct (Shieh et
al., 2000). The reduction in Chk1 expression by siRNA
(Fig. 5 A) or AS transfection (Fig. 5 D, lane 4) resulted in re-
duced phosphorylation of Chk1 at Ser-317 (pChk1) during
HU treatment.
Using the same synchronization and HU treatment proto-
col, two sequential Chk1 siRNA transfections were conducted
just before growth to confluence. Both the control and Chk1
siRNA-transfected cell populations contained 
 
 
 
60% S-phase
cells after 6 h of HU treatment as analyzed by flow cytometry
and BrdU incorporation. However, longer durations of Chk1
siRNA transfection did alter cell cycle profile, hence the
shorter time point was chosen (unpublished data). Chk1 de-
pletion was not complete, which led to the appearance of re-
sidual protein and pChk1 foci in 
 
 
 
10% of the HU-treated
cells (Fig. 5, A and B; and Fig. S3 A, available at http://
www.jcb.org/cgi/content/full/jcb.200405128/DC1). In con-
trol cells and in cells where Chk1 was not down-regulated,
pChk1 colocalized extensively with BLM and 53BP1. How-
ever, the absence of pChk1 foci was associated with a lack of
BLM or 53BP1 foci (Fig. 5 B and Fig. S3 A) and decrease in
the level of colocalization (Fig. 5 C and Fig. S3 B). The Chk1
siRNA-treated cells still stained with BrdU, indicating the
presence of stalled replication forks due to HU treatment (Fig.
S3 C, a). Transfection of control siRNA did not cause a deple-
tion of pChk1 foci nor altered its subsequent colocalization
with BrdU foci (Fig. S3 C, b).
These results suggested that Chk1 was upstream of 53BP1
and BLM in response to HU. The depletion or overexpres-
sion of Chk1 did not alter the protein levels of 53BP1 (Fig.
5, A and D). In contrast, overexpression of Chk1 in the
presence of HU resulted in enhanced BLM accumulation,
above the level obtained with HU alone (Fig. 5 D, lane 3).
Conversely, the abrogation of endogenous Chk1 expression
by Chk1 AS or Chk1 siRNA led to decreased BLM accumu-
lation (Fig. 5, A and D). To determine whether or not the
kinase activity of Chk1 was essential for BLM accumulation,
we used UCN-01, a drug known to inhibit the kinase activ-
ity of Chk1, but not that of ATR (Busby et al., 2000).
Cotreatment of UCN-01 for a short duration of 6 h did not
cause a change in the cell cycle profile of HU-treated NHFs.
Longer durations of UCN-01 treatment did alter cell cycle
profile, hence the shorter time point was chosen (unpub-
lished data). Because UCN-01 does not affect the upstream
signaling pathways to Chk1, resulting in its phosphorylation
(Busby et al., 2000), NHFs treated with UCN-01 showed
similar levels of either Chk1 or pChk1. The level of BLM
(but not 53BP1) decreased after UCN-01 treatment (Fig. 5
D, lane 5). Though pChk1 foci were visible, very little
BLM/pChk1 colocalization was observed. Similarly, pChk1
and 53BP1 did not colocalize in UCN-01–cotreated NHFs
(Fig. 5 E). Hence, activated Chk1 kinase may be required
for the correct colocalization and accumulation of BLM foci
at sites of stalled DNA replication forks.
ATR is the direct upstream regulator of Chk1 (Abraham,
2001; Bartek and Lukas, 2003). To confirm the ATR/
Chk1/53BP1/BLM/p53 pathway, we first used a pair of
isogenic U2OS cells expressing doxycycline-inducible Flag-
tagged ATR and ATR-kd (ATR-kinase defective) proteins
(Nghiem et al., 2002). Though the formation of ATR,
pChk1, BLM, and 53BP1 foci were not affected, a high
percentage of colocalization was observed only in WT
ATR but not in ATR-kd cells (Fig. S3, B and D). As a sec-
ond approach, NHFs were cotreated with HU and either
caffeine, LY294002, or wortmannin. The drug concen-
trations were selected so that ATM/ATR (for caffeine) or
all known PI3-kinases (for LY294002 and wortmannin)
would be inhibited (Sarkaria, 2003). Caffeine, LY294002,
or wortmannin treatments diminished the phosphorylation
of Chk1 (Fig. 5 F and not depicted). Neither the pro-
tein  levels of 53BP1 nor the cell cycle profile of HU-
treated NHFs were altered by 6-h cotreatment with caffeine,
LY294002, or wortmannin (unpublished data). Similar to
the effect with Chk1 siRNA, AS Chk1, and UCN-01 (Fig.
5 D), caffeine and LY294002 inhibited BLM accumulation
in response to HU treatment (Fig. 5 F). Caffeine, LY294002,
and wortmannin also diminished focal colocalization of BLM
with pChk1 or 53BP1 after HU treatment (Fig. 5, C and G;
and not depicted). These results indicated that BLM was
possibly phosphorylated, stabilized, and subsequently colo-
calized with replicational forks in an ATR- and Chk1-
dependent manner.
 
Chk1-mediated phosphorylation of BLM
 
To demonstrate Chk1-mediated in vitro phosphorylation,
reactions were performed using purified substrates and Chk1
(WT) and kinase defective (KD; Fig. S4 A, available at http:
//www.jcb.org/cgi/content/full/jcb.200405128/DC1). As
reported earlier (Shieh et al., 2000), p53 was phosphorylated
by Chk1 WT, but not by Chk1 KD (Fig. 6 A, lanes 1–4).
Chk1 WT and not Chk1 KD also phosphorylated BLM in a
dose-dependent manner (Fig. 6 A, lanes 5–8).
Recently, it has been reported that the phosphorylation of
NH
 
2
 
-terminal BLM on Thr-99 and Thr-122 is mediated by
ATR (Davies et al., 2004). To investigate whether or not
Chk1 can phosphorylate these BLM mutants, we performed
in vitro phosphorylation reactions. WT Chk1 (but not the
KD mutant) can phosphorylate the single (T99A and T122A)
and double (T99A/T122A) mutants, and WT BLM to simi-
lar extents. The in vitro phosphorylation reactions were
done in the context of both the truncated NH
 
2
 
-terminal
(1–212) region of BLM (Fig. S4 B) and the full-length pro-
tein (Fig. 6 B).
To determine whether or not endogenous Chk1 inter-
acted with endogenous BLM in vivo during replicational
stress, reciprocal immunoprecipitations were performed in
NHF cells using either BLM or Chk1 antibody. Chk1 was
present in BLM immunoprecipitates, whereas BLM was also 
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Figure 5. Accumulation of 53BP1 and BLM depends on the presence of Chk1 and ATR. (A) The accumulation of proteins in control and 
Chk1 siRNA-treated NHFs. Control (lanes 1 and 2) or Chk1 siRNA-transfected (lanes 3 and 4) NHFs were contact inhibited, split at low 
dilution, and grown either in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of HU for 6 h. Western blots were performed with 
anti-Chk1 (a), anti-pChk1 (b), anti-53BP1 (polyclonal; c), anti-BLM (C-18) (d), and anti-TBP antibodies (e). (B) The lack of Chk1 prevents the 
accumulation of pChk1, BLM, and p53. NHFs transfection and treatment was done as in A. Immunofluorescence was performed with antibodies 
against BLM (C-18)/pChk1/DNA (DAPI) (a) and 53BP1 (monoclonal)/pChk1/DNA (DAPI) (b). Fields were chosen that contained a cell in 
which Chk1 expression was not suppressed as an internal control for the cells lacking expression of Chk1. Arrows indicate position of cells 
that lack the expression of Chk1. Bars, 5  m. (C) Quantitations of Fig. 5 (B, E, and G). The histograms represent mean   SD. (D) The accumulation 
of proteins in NHFs due to treatment with UCN-01 and the transfection of Chk1 wild-type (WT) or antisense (AS). NHFs, transfected with 
Chk1 WT (lane 3) or AS (lane 4) were contact inhibited, split at low dilution, and either left untreated (lane 1) or treated with HU (lanes 2–4). 
Untransfected HU-treated cells were coincubated with UCN-01 (lane 5). Western blots were performed with anti-Chk1 (a), anti-pChk1 (b), 
anti-BLM (C-18) (c), anti-53BP1 (polyclonal; d), and anti-TBP antibodies (e). (E) UCN-01 inhibits focal colocalization of BLM/53BP1 with 
pChk1. NHFs were prepared as in D and treated with HU (a) or HU and UCN-01 (b) for 6 h. Immunofluorescence was performed with 
antibodies against pChk1/BLM (C-18) or 53BP1 (monoclonal)/BLM (ab476). (F) The accumulation of proteins in NHFs after treatment with 
caffeine and LY294002. NHFs were contact inhibited, split at low dilution, and left either untreated (lane 1) or treated (lanes 2–4) with HU. 
Coincubation was performed with either caffeine (lane 3) or LY294002 (lane 4). Western blots were performed with anti-pChk1 (a), anti-53BP1 
(polyclonal; b), anti-BLM (C-18) (c), and anti-TBP (d) antibodies. Bars, 5  m. (G) Caffeine and LY294002 inhibit focal colocalization of 53BP1 
and BLM. NHFs were prepared as in F and were treated with HU (a); HU and caffeine (b); and HU and LY294002 (c) for 6 h. Immunofluorescence 
was performed with antibodies against pChk1/BLM (C-18) or 53BP1 (monoclonal)/BLM (ab476). Bars, 5  m. 
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detected in Chk1 immunoprecipitates (Fig. 6 C). The inter-
action between Chk1 and BLM occurred only in 
 
 
 
HU con-
dition, indicating that Chk1–BLM interaction was a conse-
quence of replicational stress.
To elucidate if BLM stabilization was mediated in vivo by
Chk1-mediated phosphorylation during replicational stress,
we treated NHFs with HU in the presence or absence of
UCN-01 and LLnL (proteosome inhibitor), either singly or
in combination. Treatment with LLnL stabilizes BLM to a
similar extent as HU. Significantly, UCN-01–mediated de-
crease in the level of BLM during HU treatment was abro-
gated in concurrent presence of LLnL (Fig. 6 D). These re-
sults suggest that Chk1-mediated phosphorylation of BLM
leads to its subsequent stabilization.
Finally, to determine if Chk1-mediated BLM phosphory-
lation does indeed occur in vivo, we undertook two parallel
approaches. First, we immunoprecipitated BLM from cell
extracts when NHF was grown in the absence or presence of
HU, UCN-01, or LLnL. Correlating with the relative ex-
pression levels (Fig. 6 D, a), proportionate amounts of BLM
were immunoprecipitated (Fig. 6 E, a). Using an antibody
that specifically recognizes phosphoserine residues, we found
that immunoprecipitated BLM was hyperphosphorylated on
serine residues during replicational stress, i.e., 
 
 
 
HU condi-
tion. Though BLM was stabilized by LLnL, it was not serine
phosphorylated above the background level (Fig. 6 E, b).
In a parallel experiment, 
 
32
 
P-radiolabeled endogenous BLM
was immunoprecipitated from in vivo labeled cells treated as
in Fig. 6 D but grown in the presence of inorganic phos-
phate. The relative ratio of 
 
32
 
P-labeled immunoprecipitated
BLM under different conditions/treatments was similar to
those under nonradioactive growth conditions (unpublished
data). Hyperphosphorylation of stabilized BLM was detected
during HU-mediated replicational stress but not when the
helicase was restabilized by LLnL (Fig. 6 E).
 
Discussion
 
BLM is phosphorylated by both ATM and ATR sensor ki-
nases (Beamish et al., 2002; Davies et al., 2004). However,
Figure 6. Chk1-mediated phosphory-
lation of BLM. (A) Chk1 phosphorylates 
p53 and BLM. Recombinant Chk1 (WT 
or KD) was incubated with full-length p53 
or BLM protein in the presence of  -
32P 
ATP. The proteins were resolved by SDS-
PAGE and detected by autoradiography. 
(B) Chk1 phosphorylates BLM T99A/
T122A mutant. Phosphorylation reactions 
were performed as in A except immuno-
precipitated WT BLM or T99A/T122A 
mutant was used. (C) Chk1 and BLM 
interact in vivo. NHFs were contact 
inhibited, split at low dilution, and 
treated with HU for 6 h. Lysates (2 mg) 
were immunoprecipitated with antibodies 
against BLM (ab476) (lanes 3 and 4), 
Chk1 (lanes 6 and 7), or the corresponding 
goat IgGs (lane 5, goat; lane 8, rabbit). 
Input (lanes 1 and 2) indicates 5% of the 
lysate was used for immunoprecipitation. 
The blots were probed with BLM (ab476) 
(a) and Chk1 (b) antibodies. Lanes 1, 3, 6, 
minus HU; lanes 2, 4, 5, 7, and 8, plus 
HU. (D) Inhibition of Chk1-mediated 
phosphorylation destabilizes BLM. NHFs 
were either left untreated (lane 1) or 
treated with HU (lane 2), LLnL (lane 3), 
HU UCN-01 (lane 4), and HU UCN-
01 LLnL (lane 5). Western blots were 
performed with anti-BLM (C-18) (a) and 
anti-TBP (b) antibodies. (E) Chk1-mediated 
phosphorylation of BLM on serine resi-
dues in vivo. NHFs were treated as in D 
(for a and b) or grown in the presence 
of phosphate-free DME containing 2 mCi 
of 
32P-labeled inorganic phosphate per 
ml (for c). Lysates (2 mg) were immuno-
precipitated with antibodies against BLM 
(ab476) (lanes 1–5) or the corresponding 
IgG (lane 6). The efficiency of immuno-
precipitation was verified with (a) BLM 
(ab476) antibody. Phosphorylation on 
BLM was detected with phosphoserine 
antibody (b) or by autoradiography (c). 
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very little is known about how the DNA damage signal is
propagated to BLM by the signal transducer proteins from
these upstream sensor kinases. Investigating genetically de-
fined and untransformed isogenic human and murine cell
lines, we show BLM to be an important responder protein at
the core of the replicational stress pathway, possibly involved
in relaying the signal due to replicational stress to different
effector pathways involved in DNA repair. BLM foci accu-
mulated at the sites of stalled DNA replication forks and
DNA strand breaks within 30 min of HU treatment along
with the known DNA damage sensor proteins, 
 
 
 
-H2AX and
53BP1, indicating that it was an intermediate responder to
certain types of DNA damage (Fig. 1). BLM facilitated the
physical interaction of 53BP1 with p53, possibly because of
its (BLM’s) enhanced accumulation during S-phase (Fig. 2,
A–D). However, 53BP1 was functionally upstream of BLM
and was required for the focal accumulation of the latter to
the sites of stalled replication forks (Figs. 2 F and 3 C and
Fig. S2 A). Hence, a regulatory loop exits between BLM and
53BP1 that modulates each other’s function. However, from
these immunoprecipitation and immunofluorescence experi-
ments we cannot completely rule out the possibility that
53BP1, BLM, and p53 can also be present in a large multi-
protein complex.
When exposed to IR, H2AX becomes extensively phos-
phorylated within 1–3 min of DNA damage and colocalize
with proteins involved in both HR and nonhomologous end
joining (NHEJ; Paull et al., 2000). As also reported recently
(Davalos and Campisi, 2003), BLM foci colocalized appre-
ciably with 
 
 
 
-H2AX, and the extent of colocalization in-
creased with time, reflecting an increase in accumulation of
DNA damage (Fig. 1). However, BLM/53BP1 foci had an
appreciable degree of colocalization, even in the absence of
H2AX (Fig. 4). These results with replicational stress were
in contrast to the results with IR regarding 
 
 
 
-H2AX accu-
mulation, where 
 
 
 
-H2AX is crucial for the accumulation of
DNA repair complexes on damaged DNA (Bassing et al.,
2002; Celeste et al., 2002). In combination with existing lit-
erature, our results indicate that (a) the damage induced by
replicational stress on the DNA is different from the DSBs
induced by IR (or an IR mimicker like NCS), and (b) func-
tional redundancies exists in cells that distinguish the DNA
damage sensor proteins and their relative rates of accumula-
tion at the stalled DNA replication forks and DNA strand
breaks. Interestingly, H2AX is not required for Chk1 phos-
phorylation (Ward et al., 2004), validating our hypothesis of
a distinct cellular response due to stalled replicational forks.
It is possible that BLM plays a role in the phosphorylation of
H2AX during DNA damage by acting as an adaptor protein
between the kinases and H2AX.
53BP1 foci, but not its protein level, were dependent on
the presence of Chk1 (Fig. 5, A, B, and D). Hence, we pos-
tulate that Chk1 and/or its activated form served as a scaf-
folding protein, at which 53BP1 foci could accumulate
during replicational stress. 53BP1 is phosphorylated in re-
sponse to IR in an ATM-dependent pathway (Anderson et
al., 2001; Rappold et al., 2001; Fernandez-Capetillo et al.,
2002). However, phosphorylation of 53BP1 is not required
for its foci formation after IR exposure (Ward et al., 2003a).
Hence, apart from acting as a scaffolding protein, Chk1-
dependent phosphorylation of 53BP1 can occur during rep-
licational stress, and such a posttranslational modification
may be essential for its accurate focal colocalization at stalled
replicational forks (Fig. 5 E). These results do not exclude
the possibility that 53BP1 can also act upstream of ATR, as
it indeed does in the case of ATM (Mochan et al., 2003).
The extensive focal colocalization of pChk1, 53BP1, and
BLM in the presence of HU in NHF and WT ATR-express-
ing U2OS cells, and the lack of such colocalization due to
the concomitant presence of PI-3 kinase inhibitors (in
NHFs) or in ATR-kd U2OS cells (Fig. 5 G and Fig. S3 D),
indicated that the cell cycle checkpoint pathway, triggered
by replicational stress, was regulated primarily by ATR via
phosphorylation of Chk1 and consequent focal accumula-
tion of 53BP1/BLM. The accumulation of BLM/53BP1
foci was abrogated because of the depletion of Chk1, sug-
gesting that Chk1 could be functionally upstream of both
BLM and 53BP1 (Fig. 5 B and Fig. S3 A). BLM protein lev-
els, its focal accumulation and colocalization with pChk1,
and 53BP1 were all diminished when the kinase function of
Chk1 was inhibited by UCN-01 (Fig. 5, D and E). Apart
from Chk1, UCN-01 also inhibits the kinase activities of
Chk2 (at a higher concentration) and cTAK1. Chk2 is im-
plicated in an ATM-mediated checkpoint pathway (primar-
ily for DSBs), whereas cTAK1 is required for G2 cell cycle
arrest (Busby et al., 2000; Abraham, 2001). Overall, these
results (Fig. 5) are consistent with the hypothesis that upon
activation of an ATR-mediated checkpoint, BLM is a target
of phosphorylation and stabilization mediated by Chk1.
To investigate the possibility that Chk1-mediated phos-
phorylation of BLM, both in vitro and in vivo experiments
were performed. In vitro, WT Chk1 (and not the KD mu-
tant) phosphorylated BLM (Fig. 6 A). In vivo, endogenous
Chk1 and BLM colocalized (Fig. 5, B, E, and G) and coim-
munoprecipitated (Fig. 6 C) only in the presence of replica-
tional stress. Chk1 mediated the phosphorylation of BLM in
vivo on serine residues in HU-treated cells (Fig. 6 E). Lack
of BLM phosphorylation (due to UCN-01 treatment) led
to proteosome-mediated BLM destabilization and possible
degradation (Fig. 6 D). These experiments provide evidence
that Chk1-mediated phosphorylation of BLM is a conse-
quence of replicational stress and is involved in its subse-
quent stabilization. The phosphorylated, and hence, stabi-
lized BLM possibly interacts with 53BP1, enabling BLM
accumulation at HU-induced foci and, possibly, the trans-
mission of the DNA damage signal to downstream effector
functions. The phosphorylation-mediated stabilization of
BLM is in contrast to the role of Chk1 in the regulation of
cdc25A levels. Chk1-mediated phosphorylation of cdc25A is
coupled to its (cdc25’s) increased proteolysis during IR (So-
rensen et al., 2003). Hence, Chk1 has multiple functions in
the regulation of S-phase checkpoint.
Based on studies with DNA damaging drugs, it has been
suggested that an increase in the protein level of BLM was a
direct reflection of a G2 function for the helicase (Bischof
et al., 2001). One interpretation of our work can be that
the destabilization of BLM due to lack of functional Chk1
in the presence of replicational stress may lead to alterations
within S-phase. Though we did not see any gross change in
the cell cycle profile of HU/UCN-01–treated NHFs in 
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short 6-h treatments, the intra-S-phase perturbations can-
not be ruled out.
The NH
 
2
 
-terminal region of BLM (1–212) is phosphory-
lated at Thr-99 and Thr-122 by ATR during HU treatment
(Davies et al., 2004). However, other sites on BLM, outside
the NH
 
2
 
-terminal region, may still be phosphorylated by
ATR. The ATR-mediated phosphorylation of BLM was not
associated with controlling the accumulation of BLM at the
stalled DNA replication forks, its subsequent colocalization
with proteins involved in the DNA damage response, or in
modulating the SCE function of BLM (Davies et al., 2004).
Though Chk1 phosphorylates solely on serine residues of its
known in vivo substrates (Bartek and Lukas, 2003), it is pos-
sible that both Chk1 and ATR could compete for the same
site(s) on BLM. Alternatively, because Chk1 phosphorylated
the BLM mutants (T99A, T122A, and T99A/T122A) to a
similar extent as WT BLM in vitro (Fig. S4 B and Fig. 6 B),
Chk1 and ATR may have distinctive patterns of phosphory-
lation on BLM, leading to divergent functions. Although
ATR-mediated threonine phosphorylation of BLM is in-
volved in the recovery of cells from S-phase (Davies et al.,
2004), Chk1-mediated serine phosphorylation is involved in
BLM stabilization and its possible interaction with 53BP1
and subsequent signal transduction machinery.
Based on the aforementioned evidence, we propose that
BLM acts as a major “molecular node” in response to repli-
cational stress. BLM receives the DNA damage signal from
ATR, Chk1, and 53BP1 and, in turn, transmits the signal to
different downstream repair processes. BLM attempts to
process the stalled forks by reverse branch migration es-
pecially in the absence of significant stress. However, as
DNA damage accumulates in number and complexity, BLM
transmits the signal to pro-recombinogenic RAD51 protein,
which resolves the stalled DNA replication forks by HR
(Karow et al., 2000; Sengupta et al., 2003). BLM is required
for p53 accumulation at stalled DNA replication forks. p53
governs RAD51-dependent gene conversion via direct bind-
ing (for review see Bertrand et al., 2004). The suppression of
crossing over and the resolution of recombination interme-
diates due to the functional interaction of BLM and TopoIII
 
 
 
(Wu and Hickson, 2003) may be a necessary step for the
suppression of tumorigenesis.
BLM may be involved in transmitting the signal to both
HR and NHEJ, two of the major DNA repair pathways.
BLM is required for correct nuclear localization of RAD50/
MRE11/NBS1 complexes after replication fork arrest (Fran-
chitto and Pichierri, 2002; Davalos and Campisi, 2003).
BLM is also involved in the alignment of microhomology
elements during NHEJ (Langland et al., 2002). Functional
cross-talk exists in cells between BLM and members of the
mismatch repair pathway. ATR, BLM, and MSH6 are part
of the BASC complex (Wang et al., 2000). Recently, we
have reported that MSH2/6 colocalize, physically interact,
and stimulate the helicase function of BLM (Yang et al.,
2004).
In conclusion, we provide compelling evidence that both
53BP1 and BLM are responders during replicational stress.
Whereas BLM facilitates the physical interaction between
p53 and 53BP1, 53BP1 is responsible for the accumulation
of BLM foci at stalled replication forks. The accumulation of
BLM/53BP1 foci and the physical interaction between them
is not dependent on 
 
 
 
-H2AX. ATR and Chk1 are function-
ally upstream of BLM. Chk1 regulates the accumulation of
53BP1/BLM foci and BLM stabilization via phosphoryla-
tion. This work provides direct evidence of BLM as a protein
involved in signal transduction during replicational stress.
Materials and methods
Antibodies
The antibodies used were as follows: Anti-p53: monoclonals DO-1 (Santa
Cruz Biotechnology, Inc.); rabbit polyclonal CM1 (Signet). Anti-BLM: goat
polyclonal C-18 (Santa Cruz Biotechnology, Inc.); rabbit polyclonal ab476
(Novus). Anti-BrdU: monoclonal (Amersham Biosciences). Anti-53BP1:
monoclonal (Schultz et al., 2000); rabbit polyclonal (Anderson et al., 2001).
Anti- -H2AX: rabbit polyclonal PC-100 (Trevigen). Anti-TBP: monoclonal
58C9 (Santa Cruz Biotechnology, Inc.). Anti-Chk1: rabbit polyclonal
#2345 (Cell Signaling). Anti-phospho-Chk1 (Ser317): rabbit polyclonal
#2344 (Cell Signaling). Antiphosphoserine: monoclonal (Sigma-Aldrich).
Anti-Nucleolin (C23): monoclonal MS-3 (Santa Cruz Biotechnology, Inc.).
Secondary antibodies were purchased from Jackson ImmunoResearch Lab-
oratories and Southern Biotechnology Associates, Inc.
Cells, culture conditions, and treatments
HTERT-immortalized NHF strain GM07532 (NHF), GM07532 E6 (NHF
E6), hTERT-immortalized Bloom syndrome, BS, fibroblasts and chromo-
some-15-corrected BS fibroblasts, BS A-15 (GM03509 A-15; Sengupta et
al., 2003); WT and KO primary 53BP1 MEFs (Ward et al., 2003b); and WT
and KO H2AX MEFs (Celeste et al., 2002) were maintained as published.
BS and BS A-15 were provided by J. Shay (University of Texas, Southwest-
ern Medical Center at Dallas, Dallas, TX).
HU (Sigma-Aldrich; 1 mM, indicated time intervals) and BrdU (Sigma-
Aldrich; 150  M for 10 min) treatments were done as described previously
(Linke et al., 2003; Sengupta et al., 2003). In short, cells were synchro-
nized in G0 by growth to confluence, plated at low density for 24 h so that
most of the cells are in G1/S boundary. Cells were either left untreated or
treated with HU for indicated time intervals. Incubation of NHFs with 100
nM UCN-01 (NCI/NIH), 4 mM of caffeine (Sigma-Aldrich), and 50  M
LY294002 (Cell Signaling) was performed 1 h before, and for the duration
of HU treatment. 50  M LLnL (also known as ALLN or MG-101; Sigma-
Aldrich) was used during the HU treatment.
siRNA and AS transfection
Based on published sequences, siRNA for 53BP1 (DiTullio et al., 2002)
and Chk1 (Zhao et al., 2002) were synthesized by Dharmacon Research.
Scrambled duplex RNA, luciferase siRNA, and mock transfection were
used as controls. siRNAs were transfected by transfection reagent (Mirus
Corporation) according to the manufacturer’s protocol. Transfections with
each siRNA were done twice for every experiment. Posttransfected cells
were synchronized in G0 by growth to confluence, released at low dilu-
tions for 24 h, and subsequently treated with HU. Experiments were re-
peated three times and the cells were analyzed 48 h after transfection.
Transfections with Chk1 sense (provided by C. Prives, Columbia Univer-
sity, New York, NY) and AS (provided by S.-Y. Shieh, Academia Sinica,
Taipei, Taiwan) constructs were carried out using Lipofectamine 2000 (In-
vitrogen), according to the manufacturer’s protocol.
Western blots and immunoprecipitations
Cells were lysed in modified RIPA buffer (1 mM Tris HCl, pH 7.4, 150 mM
NaCl, 1% sodium deoxycholate, 0.1% SDS, 1mM PMSF, and protease in-
hibitors) for Western blot analysis or immunoprecipitation buffer (50 mM
Tris HCl, pH 8.0, 20% glycerol, 1 mM DTT, 0.1% NP-40, 500 mM KCl,
and protease inhibitors) for immunoprecipitations, as described previously
(Sengupta et al., 2003). Greater than 90% of the BLM was released from
the chromatin using the modified RIPA buffer. Western blot analysis and
immunoprecipitations were performed by standard protocols. The experi-
ments were repeated twice and representative blots are shown.
Microscopy
The cells were grown on coverslips in 6-well plates. Immunofluorescence
was performed as described previously (Sengupta et al., 2003). In short, the
cells were subjected to preextraction, which removed the soluble proteins
present in the nucleoplasm. The nucleus with proteins bound to the insolu-812 The Journal of Cell Biology | Volume 166, Number 6, 2004
ble DNA matrix were fixed and stained. The sites of nascent DNA replica-
tion were detected by anti-BrdU antibodies after Dnase treatment (Kennedy
et al., 2000) and visualized in a fluorescent microscope (model Axioskop;
Carl Zeiss MicroImaging, Inc.) equipped with a high performance CCD im-
aging system (IP Lab Spectrum). Alternatively, confocal fluorescent images
were collected with a confocal scan head (model MRC 1024; Bio-Rad Lab-
oratories) mounted on a microscope (model Optiphot; Nikon) with a 60 
objective. Images were analyzed by software (Bio-Rad Laboratories). At
least 100 cells were analyzed for each colocalization experiment. The ex-
periments were repeated twice. Colocalization factor is defined as [(Frac-
tion of cells having colocalization)   (Fraction of foci colocalized per
cell)]   100. For example, if 90% of the cells (fraction   0.9) show colo-
calization, and on an average 70% of the foci colocalized per cell (frac-
tion   0.7), then the colocalization factor is (0.9   0.7)   100   63.
Labeling and kinase assays
Chk1 kinase assays were performed with 300 ng of the kinase (WT or KD)
and purified His-tagged BLM (150 and 300 ng) or p53 (75 and 150 ng) ac-
cording to published protocols (Shieh et al., 2000). Chk1 WT and KD re-
combinant proteins were provided by C. Prives. p53 protein was pur-
chased from Protein One. Purification of Chk1 and BLM have been
reported previously (Shieh et al., 2000; Yang et al., 2004). Flag-tagged
pcDNA BLM (WT and mutant; T99A/T122A) have been described previ-
ously (Davies et al., 2004) and were provided by I. Hickson (Cancer Re-
search UK Laboratories, Oxford, UK). NHFs were transfected with the BLM
constructs, and the helicase was immunoprecipitated and used for in vitro
phosphorylation reactions. For in vivo 
32P labeling, NHFs were grown for
6 h in phosphate-free DME containing 2 mCi of 
32P-labeled inorganic
phosphate per milliliter in the presence of the treatments, as described.
Online supplemental material
Fig. S1 shows colocalization of 53BP1 with MRE11 and RAD51 at the sites
of stalled DNA replicational forks. Fig. S2 shows specificity of 53BP1
siRNA and the cell cycle profiles after 53BP1 siRNA transfection. Fig. S3
shows specificity of Chk1 siRNA and decreased colocalization of pChk1,
53BP1, and BLM in the absence of functional ATR. Fig. S4 shows Chk1-
mediated in vitro phosphorylation on the NH2-terminal (1–212) BLM frag-
ment. Online supplemental material (Figs. S1–S4) is available at http://
www.jcb.org/cgi/content/full/jcb.200405128/DC1.
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